
According to some comments submitted to the Center for Tobacco Products (CTP) performance evaluation under the Food and Drug Administration (FDA) given to Reagan-Udall, the FDA is in disarray and influenced by external forces rather than scientific research.
In July, after facing criticism for its handling of shortages in baby formula and the review of electronic cigarettes, the FDA appointed an independent review of its food and tobacco programs. FDA Commissioner Robert Califf chose the Reagan-Udall Foundation, a non-profit research group created by Congress to support the work of the FDA, to carry out the review.
As part of its work, the Reagan-Udall Foundation has been seeking feedback from stakeholders.
Many commentaries depict the image of an institution striving to accomplish its mission.
A commentator stated that the PMTA reviewers at the CTP Office of Science lacked autonomy to exercise "best scientific practices" in reviewing PMTAs prior to their market entrance.
The individual wrote, "Scientific dissent, even if not completely suppressed, is unwelcome and punished through various indirect means (such as a lack of tasks, projects, and other opportunities required for career development/promotion).
In some departments, such as non-clinical scientific departments, the leadership pushes a mentality of "must-haves" onto employees, which does not support the reviewers in fulfilling their basic duties to provide fair reviews using the best available science.
Another commenter claimed that an arbitrary and politically driven timeline set by external forces, such as judges, is driving the review process rather than allowing for a thorough scientific review. "When mistakes are found, CTP reviewers are blamed, when in fact the lack of sufficient time to complete the review is the mistake.
The commentator wrote: "Staff are exhausted and constantly told to do more in even less time, and are blamed for not meeting crazy deadlines. Even when they complete reviews and make scientific decisions, they can be overruled by political agendas and forced to change their decisions.
Statement:
This article is compiled from third-party information and is intended for industry exchange and learning purposes only.
This article does not represent the views of 2FIRSTS and we cannot confirm the authenticity and accuracy of its content. The translation of this article is intended solely for discussion and research within the industry.
Due to limitations in translation abilities, the translated article may not fully express the original content. Therefore, please refer to the original article for accuracy.
2FIRSTS maintains full alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.









